Clinical trial
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00269672 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00269672 |
|---|---|
| Title | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects |
| Official title | A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Vaccines, Pneumococcal Conjugate Vaccine |
| Intervention type | Biological |
| Interventions | 13-valent Pneumococcal Conjugate Vaccine |
| Enrollment | 915 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Aug 5, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: